Uber Technologies is said to be considering an acquisition of either Bird or Lime, according to a report by The Information. Bird and Lime are prominent start-ups in the electric scooter space, and both have valuations of over $1 billion.
Although it was reported that the negotiations are in early stages and there is no guarantee of a deal materializing, there has been no confirmation from any of the parties involved. Meanwhile, the CEO of Bird reportedly indicated that the company was not for sale.
Leading automakers and ridesharing companies are moving into the mobility services market which is increasingly gaining importance. Bikes and scooters are becoming a major part of this market with rapid growth being witnessed in the scooter space. Ridesharing companies are looking at providing customers with multiple booking options. In other words, customers can either book a car, a scooter or a bike on the same platform.
Uber, which acquired Jump Bikes earlier this year and rolled out its own scooters in October, is seeing a slowdown in growth in the US. The cab services provider, which is planning for an IPO next year, has also been incurring losses which might be one of the reasons the firm is looking to expand its range of mobility offerings.
The acquisition of any of the two scooter start-ups will help Uber increase its supply of scooters and also expand into more markets. Uber’s competitor Lyft is on a similar path and is making efforts to expand in the area of bikes and scooters through acquisitions and other strategies.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training